For the Treatment of Crohn’s Disease, Current and Emerging Therapies Have No Advantage in the Induction of Remission over Janssen Biotech/Merck/Mitsubishi Tanabe’s Remicade

The Crohn’s Disease Drug Market Will Increase from Approximately $3.3 Billion in 2010 to $4.5 Billion in 2020, According to Findings from Decision Resources

February 28, 2012—Burlington, Mass.—Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. gastroenterologists and managed care organization (MCO) pharmacy directors agree that induction of remission is one of the attributes that most influences their decisions regarding prescribing and formulary status determinations, respectively, in moderate to severe Crohn’s disease. Clinical data and the opinions of interviewed thought leaders indicate that key current and emerging therapies have no advantage on this attribute over Janssen Biotech/Merck/Mitsubishi Tanabe’s Remicade, the sales leading agent for Crohn’s disease.

Decision Resources’ analysis of the Crohn’s disease drug market also finds that, based on clinical data and the opinions of interviewed thought leaders, Remicade and Abbott/Eisai’s Humira have earned Decision Resources’ proprietary clinical gold standard status for the treatment of moderate to severe Crohn’s disease. Remicade and Humira have the strongest clinical profiles among key marketed products that treat moderate to severe Crohn’s disease.

“Through 2020, we do not expect any therapy in development to replace Remicade and Humira as our proprietary clinical gold standard for Crohn’s disease,” said Decision Resources Analyst Bingnan Kang, Ph.D. “While some emerging therapies hold promise, they have efficacy, safety and tolerability, and/or delivery features that prevent them from displacing these two agents.”

The findings also reveal that surveyed U.S. gastroenterologists and MCO pharmacy directors indicate that lower risk of serious infections is one of the greatest unmet needs in moderate to severe Crohn’s disease. Clinical data and the opinions of interviewed thought leaders indicate that no emerging therapies have demonstrated the potential to fulfill this unmet need.

The Crohn’s disease drug market will increase from approximately $3.3 billion in 2010 to $4.5 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. However, this moderate growth rate will mask dramatic changes as market growth from newer and emerging biological agents outpaces the decline in sales of older, established agents, which will face increasing generics erosion and declining use over the next decade.

Decision Resources’ Robust Market Forecast and Opportunities Analysis
Decision Resources provides a comprehensive view of what is happening in a specific drug market now and in the decade ahead. The research includes analysis of the unmet need and near-term drug development opportunities that exist within a drug market powered by primary research from physicians and payers. The robust market forecast and opportunities analysis is comprised of the Pharmacor 2012 advisory service and the DecisionBase 2012 report series.

About Decision Resources
Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at


All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Christopher Comfort
Decision Resources Group

Search Reports

Decision Resources Group brands include: